Kiniksa Pharmaceuticals International, plc
KNSAHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Jun 2, 2026
Scan Results
Daily timeframeKiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. With a market capitalization of $3.73B, it sits in mid-cap territory. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.
Market Cap
$3.73B
Beta
0.17
P/E (TTM)
53.22
P/E (Fwd)
27.56
EPS (TTM)
$0.91
EPS (Fwd)
$1.76
ROE
13.7%
ROA
8.2%
Cash
$468.1M
Total Debt
$9.0M
Free CF
$117.6M
52W Change
66.4%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $468.1M in cash comfortably exceeding the $9.0M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Annual free cash flow of $117.6M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 13.7% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. An ROA of 8.2% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $220.2M (2022) to $677.6M (2025), reflecting a 208% increase over the period.
The relatively low beta of 0.17 suggests KNSA is a less volatile holding compared to the broader index. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. At over 50x earnings, KNSA carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Kiniksa Pharmaceuticals International, plc and its sector.